# US Diabetes Market > US Diabetes Market Research Report: Size, Share, Trend Analysis By Types (Type 1, Type 2, Gestational diabetes), By Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test, others), By Devices (Blood glucose monitoring devices, Diabetes management devices, others) and By Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery, others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.22% - **2024:** $ 1,560 Million - **2025:** $ 1,641.43 Million - **2035:** $ 2,730 Million - **Key Players:** Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Merck & Co. (US), AbbVie (US), Johnson & Johnson (US), Eli Lilly and Company (US), AstraZeneca (GB) **Report ID:** MRFR/Pharma/12141-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-diabetes-market-13666 --- ## Market Summary ## **US Diabetes Market Overview** As per MRFR analysis, the US Diabetes Market Size was estimated at 1.42 (USD Billion) in 2023.The US Diabetes Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 3.2 (USD Billion) by 2035. The US Diabetes Market CAGR (growth rate) is expected to be around 7.131% during the forecast period (2025 - 2035). The US Diabetes Market is experiencing significant changes driven by a variety of factors. One key market driver is the increasing prevalence of diabetes, which is fueled by rising obesity rates and sedentary lifestyles. The Centers for Disease Control and Prevention (CDC) reports that nearly half of American adults have diabetes or prediabetes, contributing to heightened awareness and demand for diabetes management solutions. Additionally, advancements in technology, such as continuous glucose monitoring systems and insulin delivery devices, are transforming diabetes care, leading to improved patient outcomes and convenience. There are numerous opportunities to be explored in the US Diabetes Market, particularly through the development of digital health solutions. Telehealth services and mobile health applications can enhance patient engagement, education, and self-management, making it essential for companies to invest in these innovations. Furthermore, increasing support for personalized medicine and continuous data monitoring provides avenues for growth, allowing for tailored treatment plans that align with individual patient needs. In recent times, trends in the US Diabetes Market indicate a shift towards preventive care. Healthcare providers are increasingly focusing on early detection and intervention, recognizing the importance of lifestyle changes in managing and potentially reversing diabetes. This trend is reflected in the growing number of community programs and initiatives aimed at promoting healthier eating, physical activity, and regular health screenings. As the US continues to grapple with the diabetes epidemic, stakeholders are likely to prioritize collaborations between healthcare sectors, technology providers, and community organizations to address this pressing public health challenge effectively. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Diabetes Market Drivers** ### **Increasing Prevalence of Diabetes in the US** The US Diabetes Market Industry is witnessing remarkable growth due to the increasing prevalence of diabetes across various demographics. According to the Centers for Disease Control and Prevention (CDC), almost 34.2 million Americans have diabetes, which accounts for approximately 10.5% of the population. This staggering figure is projected to rise due to factors such as obesity and an aging population. Furthermore, the American Diabetes Association highlights that one in three adults in the US may have prediabetes, a condition that often culminates in diabetes if not addressed. These alarming trends are driving demand for diabetes management products and healthcare services, leading to significant investments by established organizations like Medtronic and Johnson & Johnson in their Research and Development initiatives to develop innovative solutions that cater to the growing patient base. ### **Technological Advancements in Diabetes Management** Technological innovations are significantly propelling the US Diabetes Market Industry. The introduction of continuous glucose monitoring systems and insulin delivery devices has transformed diabetes management. Specifically, the FDA approved over 20 new diabetes-related devices between 2021 and 2023, enhancing patient monitoring and care. Organizations like Abbott Laboratories and Dexcom have led the way in creating cutting-edge products that provide real-time glucose readings and data analytics, helping patients manage their conditions more effectively. This technological evolution not only empowers patients but also attracts investment and funding aimed at further R&D, strengthening the overall market. ### **Government Initiatives and Healthcare Policies** Government initiatives and favorable healthcare policies are becoming crucial drivers for the US Diabetes Market Industry. The Affordable Care Act, for instance, has expanded access to diabetes preventive services, which encourages early detection and treatment. According to the Kaiser Family Foundation, approximately 21 million people gained healthcare coverage under this legislation, facilitating easier access to diabetes care and management programs. Additionally, programs funded by the CDC aim to reduce diabetes risk factors through community engagement and education, helping mitigate the diabetes epidemic. These efforts foster a more conducive environment for market growth through increased patient engagement and healthcare access. ## **US Diabetes Market Segment Insights** ### **Diabetes Market Type Insights  ** The US Diabetes Market is evolving with various types of diabetes playing integral roles in shaping its overall landscape. In recent years, the classification of diabetes has gained significant attention, particularly Type 1, Type 2, and Gestational diabetes. Type 1 diabetes, often diagnosed in children and young adults, is an autoimmune condition that results in the body's inability to produce insulin. This type has prompted increasing focus on Research and Development initiatives aimed at improving treatment options and management strategies. Conversely, Type 2 diabetes, which is more prevalent among adults and linked to obesity and lifestyle choices, is a major concern in the United States due to its growth trend and impact on public health. As awareness surrounding lifestyle changes continues to propagate, Type 2 diabetes management strategies are gaining traction among healthcare professionals and patients alike, contributing to a change in treatment approaches and accessibility to diabetes care. Gestational diabetes represents a temporary condition that occurs during pregnancy, impacting both maternal and fetal health. The rising incidence of this condition has led to heightened medical attention and intervention strategies, as effective management helps prevent long-term health issues for both mother and child. The healthcare industry acknowledges the significance of managing gestational diabetes effectively, as it can lead to increased risks of developing Type 2 diabetes later in life. This aspect has resulted in growing demand for comprehensive screening and education programs targeting expectant mothers. The US Diabetes Market segmentation reflects both the complexity of diabetes types and the corresponding healthcare responses required for effective management. Each type underscores unique risk factors and management strategies, influencing market dynamics considerably. Additionally, the gravity of the diabetes epidemic in the US has galvanized local institutions and healthcare systems to address these challenges through various initiatives, from public awareness campaigns to technological advancements in diabetes management tools. The statistics surrounding diabetes indicate a necessity for ongoing investment in medical solutions and patient education, which is crucial for improving outcomes across all types.  With the prevalence of diabetes historically rising, the US Diabetes Market is positioned for further growth driven by the increasing incidence of Type 2 diabetes, the need for continued Research and Development in Type 1 therapies, and the growing awareness and management strategies surrounding gestational diabetes. This intricate interplay of factors within the Type segment reflects the broader challenges and opportunities in the healthcare landscape within the United States. Policies and programs focusing on prevention and efficient management can provide valuable support in mitigating the growing public health concern of diabetes across all segments. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Diabetes Market Test Insights  ** The Test segment within the US Diabetes Market plays a crucial role in managing diabetes and monitoring blood glucose levels. With an increasing prevalence of diabetes, effective testing methods such as Random blood sugar test and Fasting blood sugar test have gained significant attention, as they provide immediate insights into a patient's glucose levels, aiding in timely medical decisions. The Oral glucose tolerance test is notable for its ability to diagnose insulin resistance and prediabetes, making it an essential tool in early detection. Additionally, the Initial glucose challenge test holds importance for screening pregnant women, ensuring maternal and fetal health. Other tests also contribute to the comprehensive monitoring landscape, offering varied methodologies tailored to individual patient needs. The US Diabetes Market revenue is driven by an increasing awareness of diabetes management, led by healthcare initiatives focusing on early diagnosis and lifestyle influences. However, challenges such as accessibility and affordability of testing methods persist. Overall, the US Diabetes Market segmentation demonstrates vast opportunities, particularly in enhancing testing accuracy and broadening access to these vital diabetes management tools, reflecting ongoing growth trends in this sector. ### **Diabetes Market Devices Insights  ** The Devices segment of the US Diabetes Market plays a crucial role in improving the quality of life for millions of individuals living with diabetes. This segment comprises various options, including innovative blood glucose monitoring devices and diabetes management devices, which are essential tools for effective disease control. Blood glucose monitoring devices are critical as they enable patients to track their glucose levels closely, facilitating timely insulin administration and lifestyle adjustments. Diabetes management devices contribute significantly to the adherence to treatment protocols, ensuring patients can manage their condition effectively. The growing prevalence of diabetes across the United States, fueled by lifestyle factors and an aging population, drives the demand for these devices. Furthermore, advancements in technology, such as glucose monitoring patches and remote health monitoring systems, enhance patient outcomes and engagement, making devices more user-friendly and accessible. Overall, the Devices segment is characterized by continuous innovation and adaptation to patient needs, showcasing its significance within the broader US Diabetes Market landscape. The market's dynamics also present opportunities for further growth as demand for personalized healthcare solutions and connected devices increases among the population. ### **Diabetes Market Treatment Insights  ** The Treatment segment of the US Diabetes Market plays a crucial role in managing diabetes, focusing on various methods to ensure patient wellness and control blood sugar levels. Medications are pivotal, as they enable millions of patients to manage their conditions effectively, enhancing their quality of life. Insulin therapy stands out as a dominant approach, particularly for Type 1 diabetes, providing essential hormone supplementation that patients need. Transplantation, while less common, offers hope to those with severe diabetes complications, demonstrating advancements in medical approaches. Bariatric surgery is increasingly recognized for its dual benefit of weight loss and diabetes management, significantly improving metabolic outcomes for individuals with obesity-related diabetes. Collectively, these elements contribute to the growing US Diabetes Market revenue, driven by increasing awareness, rising diabetes prevalence, and ongoing Research and Development in treatment options. The US Diabetes Market segmentation showcases a diverse landscape that offers numerous opportunities for innovation and improved patient care, aligning with health initiatives focused on managing chronic diseases. ## **US Diabetes Market Key Players and Competitive Insights** The US Diabetes Market is characterized by a strong competitive landscape driven by a significant prevalence of diabetes and a growing emphasis on innovative treatment options. With millions of individuals affected by diabetes, the market has attracted numerous pharmaceutical companies, each striving to capture a share through differentiated products, effective marketing strategies, and strong distribution channels. Key players in this sector invest heavily in research and development to bring forth new therapies, ranging from insulin products to oral medications and combination therapies. As the demand for diabetes management solutions rises, market participants are continuously adapting to shifting healthcare trends, regulatory challenges, and the evolving needs of patients and healthcare providers. AstraZeneca has established a formidable presence within the US Diabetes Market by offering a range of innovative medications that address the management of Type 2 diabetes. The company's strengths lie in its robust research and development pipeline, allowing it to consistently introduce new products that cater to diverse patient needs. AstraZeneca's focus on patient-centric solutions, including medications that not only control blood sugar but also provide cardiovascular benefits, has enhanced its reputation in the market. The company also emphasizes collaborations with healthcare professionals and organizations to improve diabetes care, further solidifying its position. With a commitment to leveraging advances in technology for diabetes management, AstraZeneca remains a key player, dedicated to addressing the challenges faced by patients living with diabetes in the US. Merck brings a wealth of experience to the US Diabetes Market, with a portfolio that includes key products designed to enhance diabetes management. The company's flagship diabetes medication has gained traction among healthcare providers and patients alike, owing to its efficacy and safety profile. Merck's strengths are underscored by its continual investment in clinical research, which supports the expanded use of its products and enhances its market presence. Additionally, Merck has executed strategic mergers and acquisitions to bolster its capabilities, allowing it to tap into new therapeutic areas and expand its product offerings. In a landscape where customer loyalty and trust play significant roles, Merck's established brand and comprehensive support programs further enhance its competitive edge in the diabetes segment, ensuring it meets the diverse needs of patients across the US. **Key Companies in the US Diabetes Market Include** ## **US Diabetes Market Industry Developments** The US Diabetes Market has seen various developments recently. Notably, in September 2023, Eli Lilly received FDA approval for a new diabetes drug, enhancing its portfolio in the highly competitive landscape. Additionally, in August 2023, Dexcom announced the launch of its latest continuous glucose monitoring system, which is expected to improve patient engagement and management.  The market has also been impacted by Eli Lilly's partnership with Medtronic to integrate their technologies aimed at streamlining diabetes care. Over the past few years, the market valuation has seen significant growth, with Novo Nordisk, for instance, reporting a substantial uptick in revenue due to its innovative insulin products. Noteworthy mergers and acquisitions in this space include Boehringer Ingelheim acquiring a stake in a digital health startup in July 2023, marking a strategic move towards digitalizing diabetes management solutions.  The American Diabetes Association has also emphasized the need for better access to diabetes medications, leading to ongoing discussions on pricing and coverage, reflecting broader healthcare reform efforts initiated in 2021 that continue to shape this market. ## **Diabetes Market Segmentation Insights** ### **Diabetes Market Type Outlook** - ### **Diabetes Market Test Outlook** - ### **Diabetes Market Devices Outlook** - ### **Diabetes Market Treatment Outlook** - ## Market Drivers ### Rising Prevalence of Diabetes The increasing prevalence of diabetes in the US is a primary driver of the diabetes market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This growing number is expected to rise, leading to heightened demand for diabetes management products and services. The diabetes market is projected to reach $100 billion by 2026, driven by the need for innovative treatment options and monitoring devices. As the population ages and lifestyle-related factors contribute to the rise in diabetes cases, the market is likely to expand further, necessitating advancements in technology and healthcare solutions to manage this chronic condition effectively. ### Supportive Government Policies Supportive government policies play a pivotal role in shaping the diabetes market. Legislative measures aimed at improving access to diabetes care and treatment are being implemented at both state and federal levels. For instance, initiatives to lower insulin costs and expand insurance coverage for diabetes management are gaining momentum. In 2025, it is anticipated that government funding for diabetes research and public health initiatives will increase by 15%, further bolstering the market. These policies not only enhance patient access to necessary treatments but also encourage innovation within the diabetes market, fostering a more robust healthcare ecosystem. ### Growing Awareness and Education There is a notable increase in awareness and education regarding diabetes management among healthcare professionals and patients. Initiatives aimed at educating the public about diabetes prevention and management are gaining traction, contributing to the growth of the diabetes market. Organizations such as the American Diabetes Association are actively promoting awareness campaigns, which have led to improved understanding of the disease. This heightened awareness is likely to result in more individuals seeking medical advice and treatment, thereby increasing the demand for diabetes-related products and services. As a result, the diabetes market may experience significant growth as more people become proactive in managing their health. ### Technological Integration in Healthcare The integration of technology into healthcare practices is transforming the diabetes market. Innovations such as telemedicine, mobile health applications, and wearable devices are enhancing patient engagement and self-management. In 2025, it is estimated that the market for diabetes management apps will reach $5 billion, reflecting the growing reliance on technology for monitoring and managing diabetes. These advancements not only improve patient outcomes but also streamline healthcare delivery, making it more efficient. As technology continues to evolve, the diabetes market is likely to benefit from increased accessibility and convenience for patients, further driving market growth. ### Increased Investment in Research and Development Investment in research and development (R&D) within the diabetes market is crucial for fostering innovation and improving treatment options. Pharmaceutical companies and biotech firms are allocating substantial resources to develop new medications, insulin delivery systems, and continuous glucose monitoring devices. In 2025, R&D spending in the diabetes sector is expected to exceed $20 billion, reflecting a commitment to addressing the diverse needs of patients. This influx of funding is likely to accelerate the introduction of novel therapies and technologies, enhancing patient outcomes and driving market growth. As competition intensifies, companies that prioritize R&D may gain a competitive edge in the diabetes market. ## Future Outlook The [Diabetes Market](https://www.marketresearchfuture.com/reports/diabetes-market-2966) is projected to grow at a 5.22% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and enhanced patient management solutions. **New opportunities:** - Development of AI-driven diabetes management apps Expansion of telehealth services for diabetes care Investment in personalized insulin delivery systems By 2035, the diabetes market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Type 2 (Largest) vs. Type 1 (Fastest-Growing) In the US diabetes market, Type 2 diabetes remains the largest segment, commanding a significant portion of the market share. It affects millions, driven by lifestyle factors and increased obesity rates across different demographic groups. Type 1 diabetes, although accounting for a smaller segment, is characterized by an autoimmune response requiring lifelong management, thus presenting unique market dynamics. Growth trends indicate that Type 1 diabetes is the fastest-growing segment due to rising awareness and advancements in treatment technologies. Factors like increased diagnosis rates and improved healthcare access are driving this growth. Additionally, the development of innovative therapies and monitoring devices is influencing consumer preferences, contributing to the overall market expansion for Type 1 diabetes management options. Type 2 (Dominant) vs. Type 1 (Emerging) Type 2 diabetes is the dominant segment in the US diabetes market, largely due to its association with lifestyle factors such as obesity and inactivity. It typically affects adults, but increasing numbers of children and adolescents are also being diagnosed. This segment benefits from a range of treatment options including oral medications and lifestyle interventions. In contrast, Type 1 diabetes is classified as an emerging segment. This autoimmune condition usually manifests in childhood or adolescence and necessitates insulin therapy. The growth of Type 1 diabetes management solutions is fueled by innovative technologies that provide better blood glucose control and convenience for patients. Thus, while Type 2 diabetes continues to dominate, Type 1 diabetes is rapidly gaining attention and investment. ### By Tests: Fasting Blood Sugar Tests (Largest) vs. Random Blood Sugar Tests (Fastest-Growing) In the US diabetes market, the distribution of tests reveals that fasting blood sugar tests hold the largest market share, reflecting their established use in diabetes diagnosis and monitoring. Random blood sugar tests, while not as dominant, are experiencing rapid growth due to increased awareness and technological advancements in diagnostic tools. Other tests, such as oral glucose tolerance and initial glucose challenge tests, occupy smaller niches but are crucial in specific diagnostic scenarios. Growth trends for the tests segment are being driven by rising diabetes prevalence and the introduction of user-friendly home testing kits. The adoption of digital health tools and telemedicine has further accelerated demand for various testing methods. Innovations in testing technologies and growing public awareness about diabetes management contribute to the segment's robust growth trajectory, highlighting the need for more accessible and effective monitoring options. Fasting Blood Sugar Tests (Dominant) vs. Random Blood Sugar Tests (Emerging) Fasting blood sugar tests are a cornerstone in the diagnosis and monitoring of diabetes, valued for their reliability and long-standing clinical usage. These tests require patients to fast overnight, measuring blood glucose levels in a controlled setting, which helps in accurate diagnosis. They dominate the market due to their established protocols and acceptance among healthcare providers. On the other hand, random blood sugar tests are emerging as a vital tool in diabetes management, especially with advancements in at-home testing technologies. Their rapid uptake is driven by convenience and the ability to provide immediate insights, appealing to proactive patients and busy lifestyles. Together, these two testing methods illustrate the dynamism of the US diabetes market. ### By Devices: Blood Glucose Monitoring Devices (Largest) vs. Diabetes Management Devices (Fastest-Growing) In the US diabetes market, blood glucose monitoring devices hold the largest share, reflecting a significant portion of the market's overall distribution. These devices have been the primary choice for diabetes management due to their established technology and widespread usage among patients. In contrast, diabetes management devices are gaining traction, emerging as a critical segment that appeals to consumers seeking more comprehensive solutions for managing their condition. Growth trends within this segment indicate a shift towards more advanced technologies, driven by increased awareness of diabetes care and innovative product offerings. The market is witnessing a surge in demand for smarter diabetes management devices that integrate with smartphones and other digital platforms. User-friendly features and enhanced connectivity are primary growth drivers, pushing the market forward and attracting a younger demographic that emphasizes convenience and innovation in healthcare solutions. Blood Glucose Monitoring Devices (Dominant) vs. Diabetes Management Devices (Emerging) Blood glucose monitoring devices dominate the US diabetes market, characterized by their reliability and precision in measuring blood sugar levels. These devices have long been trusted by patients and healthcare providers, making them integral to everyday diabetes management. Conversely, diabetes management devices are carving a niche as an emerging segment. These devices encompass a range of solutions, including insulin pumps and continuous glucose monitoring systems, which offer patients more dynamic and personalized management options. The rise of technology in healthcare is enhancing their appeal, making them attractive for both patients seeking convenience and healthcare professionals advocating for comprehensive patient care. ### By Treatment: Insulin therapy (Largest) vs. Blood Sugar Treatment (Fastest-Growing) Among the segment values in the US diabetes market, insulin therapy holds the largest market share due to its widespread use and acceptance as a primary treatment for diabetes management. Medications, including oral hypoglycemics, also contribute significantly but lag behind insulin therapy. Transplantation and bariatric surgery represent niche segments with specific target groups while blood sugar treatment emerges as a promising area, reflecting a growing interest in innovative solutions for diabetes management. Growth trends for the treatment segment indicate a robust shift towards personalized medicine and more effective insulin delivery systems. The increasing prevalence of diabetes drives demand for advanced treatment options. Additionally, the focus on weight management and lifestyle modification enhances the role of bariatric surgery, while burgeoning research in blood sugar treatment solutions points to a rapid growth trajectory as new technologies and therapies are introduced, catering to a patient population that increasingly seeks integrated healthcare solutions. Insulin therapy (Dominant) vs. Blood Sugar Treatment (Emerging) Insulin therapy remains the dominant approach in diabetes treatment due to its effectiveness in managing blood glucose levels for a wide range of patients, including those with Type 1 and advanced Type 2 diabetes. This segment benefits from continuous innovation, with new formulations and delivery devices enhancing user experience and adherence. On the other hand, blood sugar treatment is an emerging segment characterized by a surge in innovative technologies and solutions aimed at improving glycemic control. This includes devices and software that enable patients to monitor their blood sugar levels more effectively while also focusing on lifestyle integration. Both segments reflect the industry's commitment to improving treatment outcomes and patient quality of life. ## Competitive Benchmarking The diabetes market in the US is characterized by intense competition and rapid innovation, driven by an increasing prevalence of diabetes and a growing demand for advanced treatment options. Major players such as Novo Nordisk (DK), Eli Lilly and Company (US), and Sanofi (FR) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and digital health solutions. These companies are not only enhancing their product portfolios but are also engaging in strategic partnerships and collaborations to expand their market reach and improve patient outcomes. The collective strategies of these firms contribute to a dynamic competitive environment, where innovation and patient-centric approaches are paramount. Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure of the diabetes market appears to be moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, catering to various patient needs while fostering competition among the leading firms. In October 2025, Eli Lilly and Company (US) announced the launch of a new digital health platform aimed at improving diabetes management through personalized treatment plans. This strategic move underscores the company's commitment to integrating technology into diabetes care, potentially enhancing patient adherence and outcomes. By leveraging data analytics and patient feedback, Eli Lilly aims to position itself as a leader in the digital health space, which is increasingly becoming a critical component of diabetes management. In September 2025, Novo Nordisk (DK) expanded its partnership with a leading technology firm to develop AI-driven solutions for diabetes care. This collaboration is expected to enhance the company's capabilities in predictive analytics, allowing for more tailored treatment options. The integration of AI into their product offerings may not only improve patient outcomes but also streamline operational efficiencies, thereby reinforcing Novo Nordisk's competitive edge in the market. In August 2025, Sanofi (FR) launched a new insulin formulation designed to provide faster absorption and improved glycemic control. This innovation reflects Sanofi's focus on research and development, aiming to meet the evolving needs of diabetes patients. By introducing advanced formulations, Sanofi seeks to differentiate itself in a crowded market, potentially capturing a larger share of the growing demand for effective diabetes therapies. As of November 2025, current trends in the diabetes market indicate a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing product offerings. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. Companies that prioritize innovation and patient-centric solutions are likely to thrive in this evolving market. ## Recent News & Developments The US Diabetes Market has seen various developments recently. Notably, in September 2023, Eli Lilly received FDA approval for a new diabetes drug, enhancing its portfolio in the highly competitive landscape. Additionally, in August 2023, Dexcom announced the launch of its latest continuous glucose monitoring system, which is expected to improve patient engagement and management.  The market has also been impacted by Eli Lilly's partnership with Medtronic to integrate their technologies aimed at streamlining diabetes care. Over the past few years, the market valuation has seen significant growth, with Novo Nordisk, for instance, reporting a substantial uptick in revenue due to its innovative insulin products. Noteworthy mergers and acquisitions in this space include Boehringer Ingelheim acquiring a stake in a digital health startup in July 2023, marking a strategic move towards digitalizing diabetes management solutions.  The American Diabetes Association has also emphasized the need for better access to diabetes medications, leading to ongoing discussions on pricing and coverage, reflecting broader healthcare reform efforts initiated in 2021 that continue to shape this market. ## Report Scope | MARKET SIZE 2024 | 1560.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1641.43(USD Million) | | MARKET SIZE 2035 | 2730.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.22% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Merck & Co. (US), AbbVie (US), Johnson & Johnson (US), Eli Lilly and Company (US), AstraZeneca (GB) | | Segments Covered | Type, Tests, Devices, Treatment | | Key Market Opportunities | Integration of digital health solutions enhances diabetes management and patient engagement in the diabetes market. | | Key Market Dynamics | Rising demand for innovative diabetes management technologies drives competitive dynamics and regulatory adaptations in the market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US diabetes market in 2024?** A: The overall market valuation was $1560.0 Million in 2024. **Q: What is the projected market valuation for the US diabetes market by 2035?** A: The projected valuation for 2035 is $2730.0 Million. **Q: What is the expected CAGR for the US diabetes market during the forecast period 2025 - 2035?** A: The expected CAGR for the US diabetes market during the forecast period 2025 - 2035 is 5.22%. **Q: Which companies are the key players in the US diabetes market?** A: Key players in the market include Novo Nordisk, Sanofi, Boehringer Ingelheim, Merck & Co., AbbVie, Johnson & Johnson, Eli Lilly and Company, and AstraZeneca. **Q: What are the market segments for diabetes treatment in the US?** A: The market segments include Type 1, Type 2, and Gestational diabetes. **Q: What was the market size for Type 2 diabetes in 2024?** A: The market size for Type 2 diabetes was $1170.0 Million in 2024. **Q: What is the projected market size for blood glucose monitoring devices by 2035?** A: The projected market size for blood glucose monitoring devices is expected to reach $1300.0 Million by 2035. **Q: How much revenue did fasting blood sugar tests generate in 2024?** A: Fasting blood sugar tests generated $400.0 Million in revenue in 2024. **Q: What is the expected growth for diabetes management devices from 2024 to 2035?** A: Diabetes management devices are projected to grow from $600.0 Million in 2024 to $1000.0 Million by 2035. **Q: What was the revenue for insulin therapy in 2024?** A: Insulin therapy generated $400.0 Million in revenue in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-diabetes-market-13666*